The use of prostate-specific antigen kinetics to stratify risk in prostate cancer

American Cancer Society: Cancer Facts and Figures, 2007. Atlanta, GA: American Cancer Society, 2007.

Partin AW, Yoo J, Carter HB, et al.: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993 150:110–114.

Partin AW, Kattan MW, Subong MS, et al.: Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 1999, 277:1445–1451.

Partin AW, Mangold LA, Lamm DM, et al.: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001, 58:843–848.

D’Amico AV, Whittington R, Malkowicz SB, et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969–974.

Kattan MW, Eastam JM, Stapleton AMF, et al.: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998, 90:766–771.

Stephenson AJ, Scardino PT, Eastham JA: Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006, 98:715–717.

D’Amico AV, Chen M-H, Roehl KA, Catalona WJ: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004, 351:125–135.

Patel DA, Presti JC Jr, McNeal JE, et al.: Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 2005, 23:6157–6162.

D’Amico AV, Renshaw AA, Sussman B, Chen MH: Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005, 294:440–447.

Freedland SJ, Aronson WJ, Kane CJ, et al.: Impact of obesity on biochemical control following radical prostatectomy for clinically localized prostate cancer. J Clin Oncol 2004, 22:446–453.

Freedland SJ, Terris MK, Presti JC Jr, et al.: Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol 2004, 172:520–524.

King CR, Freedland SJ, Terris MK, et al.: Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database. Urology 2007, 69:921–926.

Yu X, Han M, Loeb S, et al.: Comparison of methods for calculating prostate specific antigen velocity. J Urol 2006, 176:2427–2431.

King, CR, Freedland SJ, Terris MT, et al.: The optimal timing, cutoff and method of calculation of preoperative PSA velocity to predict relapse after prostatectomy: a report from the SEARCH database. Urology 2007, 69:732–737.

Carter HB, Ferrucci L, Kettermann A, et al.: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006, 98:1521–1527.

Pound CR, Partin AW, Eisenberger MA, et al.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591–1597.

Freedland SJ, Humphreys EB, Mangold LA, et al.: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005, 294:433–439.

Stephenson AJ, Shariat SF, Zelefsky MJ, et al.: Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004, 291:1325–1332.

King CR, Presti JC, Brooks JD, et al.: Postoperative prostatespecific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 2008 (in press).